Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'HUMAN-LIVER CYTOCHROME-P-450' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 64 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Nakamura, K; Hanna, IH; Cai, HL; Nishimura, Y; Williams, KM; Guengerich, FP
      Coumarin substrates for cytochrome P450 2D6 fluorescence assays

      ANALYTICAL BIOCHEMISTRY
    2. Boitier, E; Beaune, P
      Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders - An update

      CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
    3. Tuvesson, H; Wienkers, LC; Gunnarsson, PO; Seidegard, J; Persson, R
      Identification of cytochrome P4503A as the major subfamily responsible forthe metabolism of roquinimex in man

      XENOBIOTICA
    4. Hosseinpour, F; Wikvall, K
      Porcine microsomal vitamin D-3 25-hydroxylase (CYP2D25) - Catalytic properties, tissue distribution, and comparison with human CYP2D6

      JOURNAL OF BIOLOGICAL CHEMISTRY
    5. Damkier, P; Brosen, K
      Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    6. Sueyasu, M; Fujito, K; Shuto, H; Mizokoshi, T; Kataoka, Y; Oishi, R
      Protein binding and the metabolism of thiamylal enantiomers in vitro

      ANESTHESIA AND ANALGESIA
    7. Sempoux, C; Starkel, P; Stevens, M; Van Den Berge, V; Horsmans, Y
      Cytochrome P450 3A proteins are expressed in B lymphocytes but not in T lymphocytes

      PHARMACOGENETICS
    8. Damkier, P; Hansen, LL; Brosen, K
      Rifampicin treatment greatly increases the apparent oral clearance of quinidine

      PHARMACOLOGY & TOXICOLOGY
    9. Shen, SJ; Marchick, MR; Davis, MR; Doss, GA; Pohl, LR
      Metabolic activation of diclofenac by human cytochrome P450 3A4: Role of 5-hydroxydiclofenac

      CHEMICAL RESEARCH IN TOXICOLOGY
    10. Kelly, PA; Wang, H; Napoli, KL; Kahan, BD; Strobel, HW
      Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4

      EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
    11. Guengrich, FP
      Cytochrome P-450 3A4: Regulation and role in drug metabolism

      ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
    12. Totsuka, S; Watanabe, T; Koyanagi, F; Tanaka, K; Yasuda, M; Manabe, S
      Increase in urinary excretion of 6 beta-hydroxycortisol in common marmosets as a marker of hepatic CYP3A induction

      ARCHIVES OF TOXICOLOGY
    13. Damkier, P; Hansen, LL; Brosen, K
      Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    14. Loi, CM; Stern, R; Koup, JR; Vassos, AB; Knowlton, P; Sedman, AJ
      Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent

      JOURNAL OF CLINICAL PHARMACOLOGY
    15. Kudo, S; Okumura, H; Miyamoto, G; Ishizaki, T
      Cytochrome P-450 isoforms involved in carboxylic acid ester cleavage of Hantzsch pyridine ester of pranidipine

      DRUG METABOLISM AND DISPOSITION
    16. Starkel, P; Sempoux, C; Van den Berge, V; Stevens, M; De Saeger, C; Desager, JP; Horsmans, Y
      CYP 3A proteins are expressed in human neutrophils and lymphocytes but arenot induced by rifampicin

      LIFE SCIENCES
    17. KASSLERTAUB K; LITTLEJOHN T; ELLIOTT W; RUDDY T; ADLER E
      COMPARATIVE EFFICACY OF 2 ANGIOTENSIN-II RECEPTOR ANTAGONISTS, IRBESARTAN AND LOSARTAN, IN MILD-TO-MODERATE HYPERTENSION

      American journal of hypertension
    18. LEWIS DFV; LAKE BG
      MOLECULAR MODELING AND QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP STUDIES ON THE INTERACTION OF OMEPRAZOLE WITH CYTOCHROME-P450 ISOZYMES

      Toxicology
    19. THOMAS AR; CHAN LN; BAUMAN JL; OLOPADE CO
      PROLONGATION OF THE QT INTERVAL RELATED TO CISAPRIDE-DILTIAZEM INTERACTION

      Pharmacotherapy
    20. Smith, DA; Abel, SM; Hyland, R; Jones, BC
      Human cytochrome P450s: selectivity and measurement in vivo

      XENOBIOTICA
    21. Smith, G; Stubbins, MJ; Harries, LW; Wolf, CR
      Molecular genetics of the human cytochrome P450 monooxygenase superfamily

      XENOBIOTICA
    22. KUDO S; ODOMI M
      INVOLVEMENT OF HUMAN CYTOCHROME-P450 3A4 IN REDUCED HALOPERIDOL OXIDATION

      European Journal of Clinical Pharmacology
    23. KLOTZ U; HOENSCH H; SCHUTZ T; BEAUNE P; ZANGER U; BODE JC; FRITZ P
      EXPRESSION OF INTESTINAL DRUG-METABOLIZING-ENZYMES IN PATIENTS WITH CHRONIC INFLAMMATORY BOWEL-DISEASE

      Current therapeutic research
    24. IEIRI I; MAMIYA K; URAE A; WADA Y; KIMURA M; IRIE S; AMAMOTO T; KUBOTA T; YOSHIOKA S; NAKAMURA K; NAKANO S; TASHIRO N; HIGUCHI S
      STEREOSELECTIVE 4'-HYDROXYLATION OF PHENYTOIN - RELATIONSHIP TO (S)-MEPHENYTOIN POLYMORPHISM IN JAPANESE

      British journal of clinical pharmacology
    25. ZHANG H; COVILLE PF; WALKER RJ; MINERS JO; BIRKETT DJ; WANWIMOLRUK S
      EVIDENCE FOR INVOLVEMENT OF HUMAN CYP3A IN THE 3-HYDROXYLATION OF QUININE

      British journal of clinical pharmacology
    26. MURRAY M
      DRUG-MEDIATED INACTIVATION OF CYTOCHROME-P450

      Clinical and experimental pharmacology and physiology
    27. FITZSIMMONS ME; COLLINS JM
      SELECTIVE BIOTRANSFORMATION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE INHIBITOR SAQUINAVIR BY HUMAN SMALL-INTESTINAL CYTOCHROME P4503A4 - POTENTIAL CONTRIBUTION TO HIGH FIRST-PASS METABOLISM

      Drug metabolism and disposition
    28. KUDO S; UCHIDA M; ODOMI M
      METABOLISM OF CARTEOLOL BY CDNA-EXPRESSED HUMAN CYTOCHROME-P450

      European Journal of Clinical Pharmacology
    29. LOWN KS; BAILEY DG; FONTANA RJ; JANARDAN SK; ADAIR CH; FORTLAGE LA; BROWN MB; GUO WS; WATKINS PB
      GRAPEFRUIT JUICE INCREASES FELODIPINE ORAL AVAILABILITY IN HUMANS BY DECREASING INTESTINAL CYP3A PROTEIN EXPRESSION

      The Journal of clinical investigation
    30. LOWN KS; MAYO RR; LEICHTMAN AB; HSIAO HL; TURGEON DK; SCHMIEDLINREN P; BROWN MB; GUO WS; ROSSI SJ; BENET LZ; WATKINS PB
      ROLE OF INTESTINAL P-GLYCOPROTEIN (MDR1) IN INTERPATIENT VARIATION INTHE ORAL BIOAVAILABILITY OF CYCLOSPORINE

      Clinical pharmacology and therapeutics
    31. OLSEN AK; HANSEN KT; FRIIS C
      PIG HEPATOCYTES AS AN IN-VITRO MODEL TO STUDY THE REGULATION OF HUMANCYP3A4 - PREDICTION OF DRUG-DRUG INTERACTIONS WITH 17-ALPHA-ETHYNYLESTRADIOL

      Chemico-biological interactions
    32. CHANG TKH; YU L; MAUREL P; WAXMAN DJ
      ENHANCED CYCLOPHOSPHAMIDE AND IFOSFAMIDE ACTIVATION IN PRIMARY HUMAN HEPATOCYTE CULTURES - RESPONSE TO CYTOCHROME-P-450 INDUCERS AND AUTOINDUCTION BY OXAZAPHOSPHORINES

      Cancer research
    33. TOIDE K; ITOH S; NAGASAKA Y; YANAGIMOTO T; KAMATAKI T
      GENE STRUCTURE OF MOUSE CYP3A11 - EVIDENCE FOR AN ENHANCER ELEMENT WITHIN ITS 5'-FLANKING SEQUENCES

      Archives of biochemistry and biophysics
    34. ENGEL G; HOFMANN U; KROEMER HK
      PREDICTION OF CYP2DG-MEDIATED POLYMORPHIC DRUG-METABOLISM (SPARTEINE TYPE) BASED ON IN-VITRO INVESTIGATIONS

      Journal of chromatography B. Biomedical applications
    35. GERVOT L; CARRIERE V; COSTET P; CUGNENC PH; BERGER A; BEAUNE PH; DEWAZIERS I
      CYP3A5 IS THE MAJOR CYTOCHROME-P450 3A EXPRESSED IN HUMAN COLON AND COLONIC CELL-LINES

      Environmental toxicology and pharmacology
    36. JANARDAN SK; LOWN KS; SCHMIEDLINREN P; THUMMEL KE; WATKINS PB
      SELECTIVE EXPRESSION OF CYP3A5 AND NOT CYP3A4 IN HUMAN BLOOD

      Pharmacogenetics
    37. BELLOC C; BAIRD S; COSME J; LECOEUR S; GAUTIER JC; CHALLINE D; DEWAZIERS I; FLINOIS JP; BEAUNE PH
      HUMAN CYTOCHROMES P450 EXPRESSED IN ESCHERICHIA-COLI - PRODUCTION OF SPECIFIC ANTIBODIES

      Toxicology
    38. BORT R; PONSODA X; CARRASCO E; GOMEZLECHON MJ; CASTELL JV
      METABOLISM OF ACECLOFENAC IN HUMANS

      Drug metabolism and disposition
    39. PEARCE RE; RODRIGUES AD; GOLDSTEIN JA; PARKINSON A
      IDENTIFICATION OF THE HUMAN P450 ENZYMES INVOLVED IN LANSOPRAZOLE METABOLISM

      The Journal of pharmacology and experimental therapeutics
    40. ROBIN MA; MARATRAT M; LEROY M; LEBRETON FP; BONIERBALE E; DANSETTE P; BALLET F; MANSUY D; PESSAYRE D
      ANTIGENIC TARGETS IN TIENILIC ACID HEPATITIS - BOTH CYTOCHROME-P450 2C11 AND 2C11-TIENILIC ACID ADDUCTS ARE TRANSPORTED TO THE PLASMA-MEMBRANE OF RAT HEPATOCYTES AND RECOGNIZED BY HUMAN SERA

      The Journal of clinical investigation
    41. CARACO Y; WILKINSON GR; WOOD AJJ
      DIFFERENCES BETWEEN WHITE SUBJECTS AND CHINESE SUBJECTS IN THE IN-VIVO INHIBITION OF CYTOCHROME P450S 2C19, 2D6, AND 3A BY OMEPRAZOLE

      Clinical pharmacology and therapeutics
    42. HALPERT JR
      STRUCTURAL BASIS OF SELECTIVE CYTOCHROME-P450 INHIBITION

      Annual review of pharmacology and toxicology
    43. WANWIMOLRUK S; KANG W; COVILLE PF; VIRIYAYUDHAKORN S; THITIARCHAKUL S
      MARKED ENHANCEMENT BY RIFAMPICIN AND LACK OF EFFECT OF ISONIAZID ON THE ELIMINATION OF QUININE IN MAN

      British journal of clinical pharmacology
    44. BUSSE D; COSME J; BEAUNE P; KROEMER HK; EICHELBAUM M
      CYTOCHROMES OF THE P450 2C SUBFAMILY ARE THE MAJOR ENZYMES INVOLVED IN THE O-DEMETHYLATION OF VERAPAMIL IN HUMANS

      Naunyn-Schmiedeberg's archives of pharmacology
    45. WANWIMOLRUK S; WONG SM; ZHANG H; COVILLE PF; WALKER RJ
      METABOLISM OF QUININE IN MAN - IDENTIFICATION OF A MAJOR METABOLITE, AND EFFECTS OF SMOKING AND RIFAMPICIN PRETREATMENT

      Journal of Pharmacy and Pharmacology
    46. LEE C
      URINARY 6-BETA-HYDROXYCORTISOL IN HUMANS - ANALYSIS, BIOLOGICAL VARIATIONS, AND REFERENCE RANGES

      Clinical biochemistry
    47. RILEY RJ; LEEDER JS
      IN-VITRO ANALYSIS OF METABOLIC PREDISPOSITION TO DRUG HYPERSENSITIVITY REACTIONS

      Clinical and experimental immunology
    48. FIRKUSNY L; KROEMER HK; EICHELBAUM M
      IN-VITRO CHARACTERIZATION OF CYTOCHROME-P450 CATALYZED METABOLISM OF THE ANTIEMETIC TROPISETRON

      Biochemical pharmacology
    49. GOLDSTEIN JA; DEMORAIS SMF
      BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY

      Pharmacogenetics
    50. KOLARS JC; LOWN KS; SCHMIEDLINREN P; GHOSH M; FANG C; WRIGHTON SA; MERION RM; WATKINS PB
      CYP3A GENE-EXPRESSION IN HUMAN GUT EPITHELIUM

      Pharmacogenetics
    51. WATKINS PB
      NONINVASIVE TESTS OF CYP3A ENZYMES

      Pharmacogenetics
    52. SAVI P; COMBALBERT J; GAICH C; ROUCHON MC; MAFFRAND JP; BERGER Y; HERBERT JM
      THE ANTIAGGREGATING ACTIVITY OF CLOPIDOGREL IS DUE TO A METABOLIC-ACTIVATION BY THE HEPATIC CYTOCHROME P450-1A

      Thrombosis and haemostasis
    53. LOWN KS; KOLARS JC; THUMMEL KE; BARNETT JL; KUNZE KL; WRIGHTON SA; WATKINS PB
      INTERPATIENT HETEROGENEITY IN EXPRESSION OF CYP3A4 AND CYP3A5 IN SMALL-BOWEL - LACK OF PREDICTION BY THE ERYTHROMYCIN BREATH TEST

      Drug metabolism and disposition
    54. RELLING MV; NEMEC J; SCHUETZ EG; SCHUETZ JD; GONZALEZ FJ; KORZEKWA KR
      O-DEMETHYLATION OF EPIPODOPHYLLOTOXINS IS CATALYZED BY HUMAN CYTOCHROME-P450 3A4

      Molecular pharmacology
    55. PEYRONNEAU MA; DELAFORGE M; RIVIERE R; RENAUD JP; MANSUY D
      HIGH-AFFINITY OF ERGOPEPTIDES FOR CYTOCHROMES P450 3A - IMPORTANCE OFTHEIR PEPTIDE MOIETY FOR P450 RECOGNITION AND HYDROXYLATION OF BROMOCRIPTINE

      European journal of biochemistry
    56. BATT AM; MAGDALOU J; VINCENTVIRY M; OUZZINE M; FOURNELGIGLEUX S; GALTEAU MM; SIEST G
      DRUG-METABOLIZING-ENZYMES RELATED TO LABORATORY MEDICINE - CYTOCHROMES P-450 AND UDP-GLUCURONOSYLTRANSFERASES

      Clinica chimica acta
    57. CHIU SHL
      THE USE OF INVITRO METABOLISM STUDIES IN THE UNDERSTANDING OF NEW DRUGS

      Journal of pharmacological and toxicological methods
    58. YASUMORI T; NAGATA K; YANG SK; CHEN LS; MURAYAMA N; YAMAZOE Y; KATO R
      CYTOCHROME-P450 MEDIATED METABOLISM OF DIAZEPAM IN HUMAN AND RAT - INVOLVEMENT OF HUMAN CYP2C IN N-DEMETHYLATION IN THE SUBSTRATE CONCENTRATION-DEPENDENT MANNER

      Pharmacogenetics
    59. GIBALDI M
      STEREOSELECTIVE AND ISOZYME-SELECTIVE DRUG-INTERACTIONS

      Chirality
    60. LEEMANN TD; DEVI KP; DAYER P
      SIMILAR EFFECT OF OXIDATION DEFICIENCY (DEBRISOQUINE POLYMORPHISM) AND QUINIDINE ON THE APPARENT VOLUME OF DISTRIBUTION OF (+ -)-METOPROLOL/

      European Journal of Clinical Pharmacology
    61. GILLAM EMJ; BABA T; KIM BR; OHMORI S; GUENGERICH FP
      EXPRESSION OF MODIFIED HUMAN CYTOCHROME-P450 3A4 IN ESCHERICHIA-COLI AND PURIFICATION AND RECONSTITUTION OF THE ENZYME

      Archives of biochemistry and biophysics
    62. KHARASCH ED; THUMMEL KE
      HUMAN ALFENTANIL METABOLISM BY CYTOCHROME-P450-3A3 4 - AN EXPLANATIONFOR THE INTERINDIVIDUAL VARIABILITY IN ALFENTANIL CLEARANCE/

      Anesthesia and analgesia
    63. KAMATAKI T; KITADA M; KOMORI M; YOKOI T; KITAMURA R
      HUMAN FETAL LIVER CYTOCHROME-P-450 - CAPACITY TO FORM GENOTOXIC METABOLITES

      Tohoku Journal of Experimental Medicine
    64. KOLARS JC; SCHMIEDLINREN P; DOBBINS WO; SCHUETZ J; WRIGHTON SA; WATKINS PB
      HETEROGENEITY OF CYTOCHROME-P450IIIA EXPRESSION IN RAT GUT EPITHELIA

      Gastroenterology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/05/20 alle ore 11:13:12